Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. Patients may have received up to 2 prior chemotherapy regimens for small cell lung carcinoma, but no prior therapy with an m-TOR inhibitor. RAD001 will be administered orally at a dose of 10 mg daily. A cycle will be defined as 3 weeks of study drug administration, and patients will have tumor measurements every 2 cycles. Study participation will continue until disease progression or intolerable toxicities. In addition, in patients who consent, archival tumor tissue (paraffin block from original biopsy) will be collected for research purposes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03651219 -
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03958045 -
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
|
Phase 2 | |
| Completed |
NCT04381910 -
Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04885998 -
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
|
Phase 1 | |
| Active, not recruiting |
NCT03703297 -
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
|
Phase 3 | |
| Recruiting |
NCT05903092 -
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT04422210 -
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
|
Phase 1 | |
| Not yet recruiting |
NCT02875457 -
Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin
|
Phase 3 | |
| Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
| Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02551432 -
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT02262897 -
The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01943578 -
Value of Physical Capacity Tests in Lung Cancer
|
N/A | |
| Terminated |
NCT00969306 -
Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients
|
Phase 1 | |
| Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01497873 -
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00930891 -
Bevacizumab in Extensive Small Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT00958022 -
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
|
Phase 1 |